Paper Details

  1. Home
  2. Paper Details

Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells.

Author: BemarkMats, BorenäsMarcus, Cervantes-MadridDiana, CuiJean, HallbergBengt, LindDan Emil, PalmerRuth Helen, SzydzikJoanna

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the effects of repotrectinib, a third-generation ALK inhibitor, in neuroblastoma. Repotrectinib inhibited ALK signaling in vitro and exhibited strong antitumor effects in a neuroblastoma xenograft model.
Paper Details　
Original Abstract of the Article :
Neuroblastoma is the most commonly diagnosed extracranial tumor in the first year of life. Approximately 9% of neuroblastoma patients present germline or somatic aberrations in the gene encoding for anaplastic lymphoma kinase (ALK). This increases in high-risk neuroblastomas, which have a 14% freque...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920469/

データ提供：米国国立医学図書館（NLM）

Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells

This research investigates the efficacy of Repotrectinib, a third-generation ALK inhibitor, in treating neuroblastoma, a type of cancer that affects children. The study examines the effects of Repotrectinib on neuroblastoma cells in laboratory and animal models.

A Promising New Treatment for Neuroblastoma

This research offers promising results in the fight against neuroblastoma, a challenging cancer affecting children. Repotrectinib demonstrates the potential to effectively target and inhibit the growth of ALK-driven neuroblastoma cells, paving the way for new treatment options.

Hope for Children with Cancer

This research provides hope for children diagnosed with neuroblastoma. It underscores the importance of ongoing research and development of targeted therapies that can effectively combat this type of cancer.

Dr. Camel's Conclusion

This research is a beacon of hope in the fight against childhood cancer. Like a mirage that promises water in a parched desert, Repotrectinib offers a glimmer of hope for children battling neuroblastoma. This research demonstrates the power of scientific innovation in finding solutions to challenging medical problems.

Date :
  1. Date Completed 2020-11-06
  2. Date Revised 2021-01-10
Further Info :

Pubmed ID

31852910

DOI: Digital Object Identifier

PMC6920469

Related Literature

Article Analysis
・Effects of repotrectinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.